by Bruce Sylvester: Following a transient ischemic attack (TIA), quick aspirin treatment can significantly reduce the risk of a major stroke in the next few days, researchers reported… read more.
by Bruce Sylvester: One dosing with methylene blue appears to increase MRI-based response in brain areas that control short-term memory and attention, researchers reported on June 28 in… read more.
by Bruce Sylvester: Women who suffer migraines appear to have an increased risk of heart attacks and strokes as well as a higher rate of mortality from cardiovascular… read more.
by Bruce Sylvester: Pioglitazone shows efficacy against the progression of nonalcoholic steatohepatitis, or NASH, a chronic liver disease caused by a buildup of fat. Researchers reported this finding… read more.
by Bruce Sylvester: Ketamine reduced suicidal thoughts in a small group of patients with treatment-resistant depression, researchers reported on May 10, 2016 in the Journal of Clinical Psychiatry.
by Bruce Sylvester: A single exposure to general anesthesia does not lead to a cognitive risk in healthy children under age three, researchers reported On June 7, 2016… read more.
by Bruce Sylvester: Researchers have identified an across-the-board cardiovascular benefit for patients treated with a diabetes drug, liraglutide, with decreases reported in overall risk of heart attack, stroke,… read more.
by Bruce Sylvester: Researchers from a randomized phase III trial report that addition of temozolomide (Temodar) chemotherapy during short-course radiation therapy, followed by monthly maintenance doses of temozolomide,… read more.
by Bruce Sylvester: Anti-PD-L1 immunotherapy atezolizumab (TECENTRIQ) has shown efficacy in previously untreated patients with advanced bladder cancer who are ineligible for standard treatment with cisplatin.
by Bruce Sylvester: Investigative rovalpituzumab tesirine (Rova-T) appears to be safe and shows efficacy in treating advanced small cell lung cancer (SCLC), researchers reported in June, 2016 at… read more.
by Bruce Sylvester: A follow-up evaluation of subjects from the phase 1b trial (KEYNOTE-001) of newly diagnosed and previously treated patients with advanced melanoma revealed a 40% survival… read more.